What are thrombosis risk and management considerations in COVID-19?

Publication Title

ACC Feature | Key Questions on COVID-19 and Cardiovascular Disease

Authors

Geoffrey D. Barnes
Adam Cuker
Tyler J Gluckman, Providence Heart and Vascular Institute, Portland, OR, USA.Follow
Gregory Piazza
Deborah M. Siegal

Document Type

Article

Publication Date

4-22-2020

Keywords

cards; cards publication; 2019-nCoV

Abstract

Principal Guidance: The apparent increased thrombotic risk in COVID-19 patients is sufficient to recommend pharmacological VTE prophylaxis in all hospitalized patients unless contraindicated; D-dimer levels may be valuable for clinical monitoring, but there is currently no evidence supporting its use to guide anticoagulation intensity beyond clinical judgment; post-discharge VTE prophylaxis with a DOAC should be considered.

Clinical Institute

Cardiovascular (Heart)

Specialty/Research Institute

Cardiology

Specialty/Research Institute

Infectious Diseases